Estrella Immunopharma (ESLA) vs Metagenomi Therapeutics (MGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Metagenomi Therapeutics (MGX) has outperformed Estrella Immunopharma (ESLA) over the past year, losing 62.6% versus a loss of 78.9%. Metagenomi Therapeutics is the larger company by market cap ($21.4 million vs $14.1 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ESLA | MGX |
|---|---|---|
| Share price | $0.321 | $0.565 |
| Market cap | $14.11M | $21.36M |
| 1-day change | -5.70% | -7.95% |
| YTD return | -79.42% | -65.12% |
| 1-year return | -78.88% | -62.58% |
| 5-year return | -96.78% | — |
| EPS (TTM) | $-0.29 | $-2.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $25.21M |
| Revenue growth (YoY) | — | -51.79% |
| Net income (latest FY) | $-13.06M | $-87.87M |
| Operating margin | — | -380.85% |
| Net margin | — | -348.54% |
| 52-week high | $2.27 | $1.87 |
| 52-week low | $0.24 | $0.562 |
| Distance from 52-week high | -85.86% | -69.79% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +3638.32% | +1138.94% |
| Average volume | 2.04M | 163.21K |
| Shares outstanding | 43.97M | 37.81M |
| Employees | — | 113 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGX has outperformed ESLA by 16.3 percentage points over the past year.
About Estrella Immunopharma
ESLA stock →Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Metagenomi Therapeutics
MGX stock →Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
ESLA vs MGX FAQ
Which is bigger, Estrella Immunopharma or Metagenomi Therapeutics?
Metagenomi Therapeutics (MGX) is larger, with a market capitalization of $21.36M compared with $14.11M for Estrella Immunopharma (ESLA).
Which stock has performed better over the past year, ESLA or MGX?
MGX returned -62.58% over the past 12 months, compared with -78.88% for ESLA (price return, excluding dividends). Past performance does not predict future results.
Are Estrella Immunopharma and Metagenomi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.